1. 1) Committee of Brain Tumor Registry of Japan. Report of brain tumor registry of Japan (2001–2004) 13th Edition. Neurol Med Chir (Tokyo) 54 (Suppl): 9–102, 2014
2. 2) Stupp R, Hegi ME, Mason WP, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459–466, 2009
3. 3) Bloch O, Crane CA, Fuks Y, et al.: Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro-oncology 16: 274–279, 2014
4. 4) Del Vecchio CA, Li G, Wong AJ: Targeting EGF receptor variant III. tumor-specific peptide vaccination for malignant gliomas. Expert Rev Vaccines 11: 133–144, 2012
5. 5) Hashimoto N. Cancer Immunotherapy for Gliomas: Overview and Future Directions. Neurol Med Chir (Tokyo) 56: 355–360, 2016